READ-ONLY DIGITIZATION RESULT
Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial.
J Am Heart Assoc · 2025-Aug-05 · PMID 40728174
Panel C质量警告待 EXE 对齐验证
NYHA class III-IV symptoms
Figure 6. Cumulative probability of New York Heart Association class III to IV symptoms occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. NYHA class III‐IV symptoms in (A) the whole subanalysis cohort and (B‐F) subgroups of this cohort with the following baseline characteristics: (B) HbA1c < 5.7%, (C) HbA1c 5.7 to < 6.5%, (D) BMI < 25, (E) BMI 25 to < 30, and (F) BMI ≥30. BMI indicates body mass index; 1‐yr KM% indicates Kaplan–Meier cumulative incidence at 1 year; Dapa, dapagliflozin; HbA1c, hemoglobin A1c; and NYHA, New York Heart Association.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 2 | 1 | 0.6406 | 0.9468 | 15.3750 | 9.4681 | 149 | 164 |
| 2 | 2 | 0.6458 | 0.9468 | 15.5000 | 9.4681 | 150 | 164 |
| 2 | 3 | 0.6510 | 0.9468 | 15.6250 | 9.4681 | 151 | 164 |
| 2 | 4 | 0.6562 | 0.9468 | 15.7500 | 9.4681 | 152 | 164 |
| 2 | 5 | 0.6615 | 0.9468 | 15.8750 | 9.4681 | 153 | 164 |
| 2 | 6 | 0.6667 | 0.9468 | 16.0000 | 9.4681 | 154 | 164 |
| 2 | 7 | 0.6719 | 0.9468 | 16.1250 | 9.4681 | 155 | 164 |
| 2 | 8 | 0.6771 | 0.4681 | 16.2500 | 4.6809 | 156 | 209 |
| 2 | 9 | 0.6823 | 0.4681 | 16.3750 | 4.6809 | 157 | 209 |
| 2 | 10 | 0.6875 | 0.4681 | 16.5000 | 4.6809 | 158 | 209 |
| 2 | 11 | 0.6927 | 0.4681 | 16.6250 | 4.6809 | 159 | 209 |
| 2 | 12 | 0.6979 | 0.4681 | 16.7500 | 4.6809 | 160 | 209 |
| 2 | 13 | 0.7031 | 0.4681 | 16.8750 | 4.6809 | 161 | 209 |
| 2 | 14 | 0.7083 | 0.4681 | 17.0000 | 4.6809 | 162 | 209 |
| 2 | 15 | 0.7135 | 0.4681 | 17.1250 | 4.6809 | 163 | 209 |
| 2 | 16 | 0.7188 | 0.4681 | 17.2500 | 4.6809 | 164 | 209 |
| 2 | 17 | 0.7240 | 0.4681 | 17.3750 | 4.6809 | 165 | 209 |
| 2 | 18 | 0.7292 | 0.4681 | 17.5000 | 4.6809 | 166 | 209 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T17:30:40+00:00 |